Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Vistin Pharma ASA ( (DE:VP4) ) has provided an update.
Vistin Pharma ASA reported a strong financial performance in the first quarter of 2025, with a revenue increase to MNOK 115 and a 14% rise in sales volume compared to the same period last year. The company’s EBITDA grew by 48% to MNOK 30, driven by increased sales volume, product mix, and cost improvements. Despite operational challenges, including a reactor replacement, the company maintained good production levels and proposed a dividend of NOK 1.25 per share, indicating a positive outlook for stakeholders.
More about Vistin Pharma ASA
Vistin Pharma ASA is a pharmaceutical company based in Oslo, Norway, primarily engaged in the production and sale of pharmaceutical products. The company focuses on manufacturing high-quality metformin, a medication used to treat type 2 diabetes, and aims to maintain a strong market presence in the pharmaceutical industry.
Technical Sentiment Signal: Sell
Current Market Cap: €87.39M
See more insights into VP4 stock on TipRanks’ Stock Analysis page.